Washington Research Foundation
VC Fund
Seattle, United States
Washington Research Foundation is a VC fund in Seattle focused on Biotechnology and Health Care. The Seattle-based Washington Research Foundation supports groundbreaking technology in the life sciences, information technology and physical sciences fields. By advancing brilliant research and early-stage entrepreneurs, we help to grow Washington's technology economy. WRF Capital is the seed fund branch of the Washington Research Foundation.Our mission is to help local companies and institutions manage intellectual property and business. We are one of the leading venture capitalists in the Northwest, and our financial returns are invested back into research and initiatives that support new company spinouts. We help to create a vibrant research and enterprise community.
- Total investments:
- 61
- Last investment:
- Lead investor:
- 16%
Last updated:
For AI agents: llms.txt
Industries Washington Research Foundation invests in
Stages Washington Research Foundation invests in
Countries Washington Research Foundation invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Barry Forman
|
|||
C. Kent Carlson
|
|||
Jeff Eby
|
|||
Ronald S. Howell
|
|||
William J. Canastaro
|
|||
| See all 9 contacts → | |||
Investment Focus
Industry
- Biotechnology 29 (48%)
- Health Care 20 (33%)
- Medical 8 (13%)
- Pharmaceutical 7 (11%)
- Life Science 6 (10%)
Stage
- Series A 17 (28%)
- Series B 14 (23%)
- Seed 11 (18%)
- Series C 6 (10%)
- Funding Round 3 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Barry Forman
Director
|
Director | Total investments: 0 | Find email | |
|
C. Kent Carlson
Director
|
Director | Total investments: 0 | Find email | |
|
Jeff Eby
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
|
Ronald S. Howell
CEO
|
CEO | Total investments: 0 | Find email | |
|
William J. Canastaro
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Biobase
|
The Agentic OS & Infrastructure Layer for Clinical Data | Pre-Seed / Jul 08, 2026 | |
Institute for Protein Design
|
The mission of the University of Washington Institute for Protein Design is to design a new world of proteins to address 21st century challenges in medicine, energy and technology. The Institute for Protein Design was established in 2012, and is building on strengths within the University of Washington and Seattle more generally. Protein designrequires high-level expertise and talent in computing and software, biochemistry, genome sciences, biological structure, pharmacology, immunology and other basic science disciplines, as well as clinical medicine. They are marshaling deep institutional strengths in our faculty, scientific staff, postdoctoral fellows and graduate students, their partners from collaborating institutions, innovator networks, and from the computer and biotechnology industries — bringing extraordinary expertise to bear on a singular focus to advance the potential of protein design.Over the past 16 years, UW researchers have made significant progress in protein design and protein structure prediction, developing the world leading Rosetta software. During this period, UW scientists have developed methods for designing proteins with a wide range of new functions, including catalysts for chemical reactions, HIV and RSV vaccine candidates, and flu virus inhibitors. The IPD integrates these strengths in protein design with Seattle-area expertise in biochemistry, engineering, computer science and medicine, and leverages the exceptional Seattle strength in the software industry. | $7M / Grant / Mar 19, 2026 | |
|
Accipiter Biosciences
|
Accipiter Biosciences is a biotechnology company. | $12.7M / Seed / Nov 06, 2025 | |
Viata
|
Viata offers hotel booking and comparative pricing for users. | $100K / Grant / Dec 03, 2024 | |
Monod Bio
|
Monod Bio is a life sciences company developing biosensors for protein and other analyte detection. Its biosensor platform combines binding, transduction, and amplification to detect a range of target molecules. It utilizes recent advances in computational protein engineering to create highly modular bio-sensing nano switches that stimulate rapid,sensitive, and inexpensive analytical assays.Monod Bio was founded in 2021 and is headquartered in Seattle, Washington. | $25M / Seed / Aug 15, 2022 | |
SEngine Precision Medicine
|
SEngine Precision Medicine uses algorithms and 3D organoid technology to develop drugs with more efficacy. It empowers patients and oncologists with more informed treatment options. The company's technology simultaneously tests more than 200 cancer drugs against a patient's unique tumor organoid outside the body. The results decode themost effective and least toxic treatment options that DNA sequencing alone cannot reveal. Its proprietary platform leverages the aggregated, anonymized test results to develop new cancer-fighting drugs. | $10M / Series A / Jul 28, 2022 | |
Cyrus Biotechnology
|
Cyrus Biotechnology builds software tools to accelerate basic research in biotech, pharma, and industrial biotechnology. Cyrus Bench delivers an enterprise version of the Rosetta molecular modeling and design toolkit, with the associated array of bio-molecular computation tools. It was founded in 2014 and headquartered in Seattle, Washington. | $18M / Series B / Dec 06, 2021 | |
Outpace Bio
|
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need. | $30M / Series A / Mar 31, 2021 | |
AdaptX
|
AdaptX (formerly MDmetrix) is a healthcare data analytics, visualization, and AI company that serves hospitals and surgery centers. By empowering medical leaders and frontline clinicians to access, analyze, and improve clinical and workflow outcomes, AdaptX enables providers to improve care and lower costs, transforming clinical operations. Foundedin Seattle in 2016, AdaptX was spun out of Seattle Children's Hospital. | $1.1M / Seed / May 25, 2020 | |
Medcurity
|
Medcurity is a developer of a compliance management platform used to perform complex HIPAA and security requirements for healthcare systems. Its platform enables users to build or complement their HIPAA privacy and security program with the intuitive tools and helpful guides available. | $200K / Seed / May 04, 2020 | |
| See all 61 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Washington Research Foundation invest in?
Washington Research Foundation invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 61 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Washington Research Foundation?
Public channels for Washington Research Foundation include X (Twitter), the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Washington Research Foundation?
The team at Washington Research Foundation includes Barry Forman (Director), C. Kent Carlson (Director) and Jeff Eby (Chief Financial Officer), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
